Stryker price target raised to $425 from $400 at RBC Capital

RBC Capital raised the firm’s price target on Stryker (SYK) to $425 from $400 and keeps an Outperform rating on the shares after hosting a non-deal roadshow with its management team. The strategic objectives of the MedSurg and Neurotechnology – MSNT – segment are focused on strong innovation and targeted execution, the analyst tells investors in a research note. RBC further cites Stryker’s bullish outlook on its growth potential, driven by durable innovation, positive ongoing trends, and a strategic vision to enter one of five attractive growth adjacencies.